{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:06:42Z","timestamp":1791295602937,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2007,3,24]],"date-time":"2007-03-24T00:00:00Z","timestamp":1174694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Spironolactone improves prognosis in severe heart failure (HF). We investigated its effects in patients with mild\u2013moderate HF treated with an ACE inhibitor and beta-blocker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Randomised, double-blind, parallel-group, 3-month comparison of placebo and spironolactone (25 mg daily) in 40 patients in New York Heart Association (NYHA) class I (20%), II (70%) or III (10%), with a left ventricular ejection fraction of &amp;lt;40%.<\/jats:p>\n                    <jats:p>The mean (standard error) changes from baseline in the spironolactone and placebo groups were, respectively: i) B-type natriuretic peptide (BNP) \u221253.4(22.2) pg\/mL and +3.3(12.1) pg\/mL, P=0.04, ii) pro-collagen type III N-terminal amino peptide (PIIINP) \u22120.6(0.2) \u03bcmol\/L and +0.02(0.2) \u03bcmol\/L, P=0.02 and iii) creatinine +10.7(3.2) \u03bcmol\/L and \u22120.3(2.6) \u03bcmol\/L, P=0.01.<\/jats:p>\n                    <jats:p>Compared with placebo, spironolactone therapy was associated with a reduction in self-reported health-related quality of life: change in visual analog score: \u22126 (3) vs. +6 (4); P=0.01.<\/jats:p>\n                    <jats:p>No differences were observed on other biochemical, neurohumoral, exercise and autonomic function assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with mild\u2013moderate HF, spironolactone reduced neurohumoral activation (BNP) and a marker of collagen turnover (PIIINP) but impaired renal function and quality of life. The benefit\u2013risk ratio of aldosterone blockade in mild HF is uncertain and requires clarification in a large randomised trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ejheart.2006.10.005","type":"journal-article","created":{"date-parts":[[2006,11,28]],"date-time":"2006-11-28T10:32:22Z","timestamp":1164709942000},"page":"429-434","source":"Crossref","is-referenced-by-count":47,"title":["Effects of Aldosterone Receptor Blockade in Patients with Mild\u2013Moderate Heart Failure Taking a Beta-Blocker"],"prefix":"10.1093","volume":"9","author":[{"given":"Colin","family":"Berry","sequence":"first","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Vito","sequence":"additional","affiliation":[{"name":"Department of Applied Physiology, University of Strathclyde , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Galloway","sequence":"additional","affiliation":[{"name":"Institute for Sports Research, University of Stirling , Stirling ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Seed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Queen Elizabeth Building, Royal Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vallance","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, University College Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Sewart","family":"Hillis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McMurray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Western Infirmary , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,3,24]]},"reference":[{"key":"2026020203465975200_ejhf2006-10-005-bib-0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"24","key":"2026020203465975200_ejhf2006-10-005-bib-0002","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary \u2014 a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure)","volume":"104","author":"Hunt","year":"2001","journal-title":"Circulation"},{"issue":"21","key":"2026020203465975200_ejhf2006-10-005-bib-0003","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"2026020203465975200_ejhf2006-10-005-bib-0004","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.98.12.1184","article-title":"Clinical effects of beta-adrenergic blockade in chronic heart failure \u2014 a meta-analysis of double-blind, placebo-controlled, randomized trials","volume":"98","author":"Lechat","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"2026020203465975200_ejhf2006-10-005-bib-0005","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/hrt.81.3.297","article-title":"QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion","volume":"81","author":"Bonnar","year":"1999","journal-title":"Heart"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0006","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neurendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0007","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0735-1097(93)90042-Y","article-title":"Activation of neurohormonal systems in post-infarction left ventricular dysfunction","volume":"22","author":"Rouleau","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2026020203465975200_ejhf2006-10-005-bib-0008","first-page":"21","article-title":"Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population","volume":"86","author":"McDonagh","year":"2001","journal-title":"Heart"},{"issue":"1","key":"2026020203465975200_ejhf2006-10-005-bib-0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"8","key":"2026020203465975200_ejhf2006-10-005-bib-0010","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/01.ATV.0000081742.92006.59","article-title":"Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase","volume":"23","author":"Achan","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2026020203465975200_ejhf2006-10-005-bib-0011","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2337\/diabetes.51.5.1596","article-title":"C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study","volume":"51","author":"Freeman","year":"2002","journal-title":"Diabetes"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026020203465975200_ejhf2006-10-005-bib-0013","first-page":"354","article-title":"Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","volume":"17","author":"Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","year":"1996","journal-title":"Eur Heart J"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0014","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0735-1097(01)01383-3","article-title":"Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction","volume":"38","author":"Stanek","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0015","first-page":"206A","article-title":"Beneficial effect of spironolactone an brain natriuretic peptide in severe congestive heart failure","volume":"35","author":"Rousseau","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2026020203465975200_ejhf2006-10-005-bib-0016","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0017","first-page":"221","article-title":"Mechanisms contributing to the survival benefit with aldosterone antagonist therapy in heart failure. Effects on neurohormones and cardiac fibrosis: a substudy of RALES","volume":"21","author":"Zannad","year":"2000","journal-title":"Eur Heart J"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0018","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Aldosterone blockade improves endothelial nitric oxide bioactivity, left ventricular remodelling and QT interval length in mild heart failure patients already on optimal therapy including beta-blockers","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"issue":"5","key":"2026020203465975200_ejhf2006-10-005-bib-0019","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2004.01.010","article-title":"Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure","volume":"10","author":"Cicoira","year":"2004","journal-title":"J Card Fail"},{"issue":"5","key":"2026020203465975200_ejhf2006-10-005-bib-0020","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0735-1097(01)01539-X","article-title":"Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction","volume":"38","author":"Hayashi","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1291\/hypres.24.99","article-title":"High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients","volume":"24","author":"Sato","year":"2001","journal-title":"Hypertens Res"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0022","volume-title":"UK population norms for EQ-5D: Discussion paper","author":"Kind"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejheart.2005.01.012","article-title":"The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study","volume":"7","author":"Calvert","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"2026020203465975200_ejhf2006-10-005-bib-0024","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/eurheartj\/ehi023","article-title":"Spironolactone improves lung diffusion in chronic heart failure","volume":"26","author":"Agostoni","year":"2005","journal-title":"Eur Heart J"},{"issue":"12","key":"2026020203465975200_ejhf2006-10-005-bib-0026","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.amjcard.2004.03.015","article-title":"Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy","volume":"93","author":"Abiose","year":"2004","journal-title":"Am J Cardiol"},{"issue":"10","key":"2026020203465975200_ejhf2006-10-005-bib-0027","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2003.12.033","article-title":"Effects of ACE gene insertion\/deletion polymorphism on response to spironolactone in patients with chronic heart failure","volume":"116","author":"Cicoira","year":"2004","journal-title":"Am J Med"},{"issue":"2","key":"2026020203465975200_ejhf2006-10-005-bib-0028","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2026020203465975200_ejhf2006-10-005-bib-0029","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to angiotensin converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"issue":"6","key":"2026020203465975200_ejhf2006-10-005-bib-0030","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"2026020203465975200_ejhf2006-10-005-bib-0031","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0002-9149(00)01046-8","article-title":"Effects of Spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure","volume":"86","author":"Korkmaz","year":"2000","journal-title":"Am J Cardiol"},{"issue":"7","key":"2026020203465975200_ejhf2006-10-005-bib-0032","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","article-title":"Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure","volume":"37","author":"Yee","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2026020203465975200_ejhf2006-10-005-bib-0033","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0034","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1136\/heart.85.4.e8","article-title":"Serious adverse events experienced by patients with chronic heart failure taking spironolactone","volume":"85","author":"Berry","year":"2001","journal-title":"Heart"},{"key":"2026020203465975200_ejhf2006-10-005-bib-0035","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2006.10.005","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/4\/429\/66615346\/eurjhf_9_4_429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/4\/429\/66615346\/eurjhf_9_4_429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:47:08Z","timestamp":1770022028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/9\/4\/429\/8443630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,24]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2007,3,24]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2006.10.005","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,4]]},"published":{"date-parts":[[2007,3,24]]}}}